Drug Shortage Active
LIRAGLUTIDE is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
LIRAGLUTIDE (liraglutide) by Hikma is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2024.
Drug data last refreshed 19h ago
Glucagon-like Peptide-1 (GLP-1) Agonists
GLP-1 Receptor Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
Efficacy of Liraglutide Therapy in Patients With IPAA
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Worked on LIRAGLUTIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.